Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Stemtech (STEK) EBITDA Margin (2020 - 2025)

Stemtech's EBITDA Margin history spans 5 years, with the latest figure at 95.34% for Q3 2025.

  • For Q3 2025, EBITDA Margin rose 12340.0% year-over-year to 95.34%; the TTM value through Sep 2025 reached 44.5%, up 8167.0%, while the annual FY2024 figure was 81.25%, 2018.0% up from the prior year.
  • EBITDA Margin for Q3 2025 was 95.34% at Stemtech, up from 170.8% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 1624.65% in Q3 2022 and bottomed at 1925.71% in Q2 2022.
  • The 5-year median for EBITDA Margin is 89.08% (2023), against an average of 117.63%.
  • The largest YoY upside for EBITDA Margin was 226213bps in 2022 against a maximum downside of -189688bps in 2022.
  • A 5-year view of EBITDA Margin shows it stood at 44.53% in 2021, then soared by 81bps to 8.59% in 2022, then plummeted by -938bps to 89.08% in 2023, then skyrocketed by 195bps to 85.04% in 2024, then crashed by -212bps to 95.34% in 2025.
  • Per Business Quant, the three most recent readings for STEK's EBITDA Margin are 95.34% (Q3 2025), 170.8% (Q2 2025), and 89.09% (Q1 2025).